Regencell Bioscience Holdings Limited Stock Prediction and Forecast [RGC]
1 extracted signal · 1 resolved · 0 still active
StockInvest.usIndependent analyst profile- Source published
- 11 Sept 2025, 03:17 UTC
- Recorded by Tahlil Plus
- 18 May 2026, 20:23 UTC
![Video preview for Regencell Bioscience Holdings Limited Stock Prediction and Forecast [RGC]](https://i.ytimg.com/vi/VD6w_-4Mohc/hqdefault.jpg)
AI-generated source summary
The analysis focuses on RegentCell Bioscience Holdings (RGC). Since September 4th, the system has classified it as a sell candidate with a score of -2.578, despite a 3.66% gain and a 0.73% average daily gain over the past 5 days. The short-term trend is declining, suggesting a selling opportunity. A break above the upper trend line at $25.78 would indicate a slower decline and a potential trend shift. The three-month trend projects a change of -87.39%, with a potential range from -100% to -75.58%. The 12-month analysis forecasts a change between 20.76% and 8261.38%. The stock experiences resistance around $13.50 and support around $13.30. Volume is decreasing with the price, which is a positive sign because the volume usually follows the price. The stock is assigned a 'strong sell' rating by analysts, who have not recently engaged in insider trading.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
StockInvest.us
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.